The effect of budesonide and formoterol in one pressurized metered-dose inhaler on patient-reported outcomes in adults with mild-to-moderate persistent asthma

References

• National Asthma Education and Prevention Program. Expert panel report 3: guidelines for the diagnosis and management of asthma (full report 2007). Bethesda, MD: August 2007. NIH Publication No. 08–4051
   Google Scholar
• Barnes PJ, Jonsson B, Klim JB. The costs of asthma. Eur Respir J 1996;9:636–42
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J 2002;19:182–91
   PubMed Web of Science ®Google Scholar
• Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994;344:219–24
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997;337:1405–11
   Google Scholar
• O’Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001;164:1392–97
   Google Scholar
• Zetterström O, Buhl R, Mellem H, et al. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur Respir J 2001; 18:262–8
   Google Scholar
• Shapiro G, Lumry W, Wolfe J, et al. Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma. Am J Respir Crit Care Med 2000;161:527–34
   PubMed Web of Science ®Google Scholar
• Kavuru M, Melamed J, Gross G, et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, doubleblind, placebo-controlled trial. J Allergy Clin Immunol 2000;105:1108–16
   PubMed Web of Science ®Google Scholar
• Goldsmith DR, Keating GM. Budesonide/formoterol: a review of its use in asthma. Drugs 2004;64:1597–618
   PubMed Web of Science ®Google Scholar
• Markham A, Jarvis B. Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma. Drugs 2000;60:1207–33
   PubMed Web of Science ®Google Scholar
• Greenstone IR, Ni Chroinin MN, Masse V, et al. Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database Syst Rev 2005:CD005533
   Google Scholar
• Masoli M, Weatherall M, Holt S, Beasley R. Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma. Thorax 2005;60:730–4
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention – updated 2007. [Accessed at www.ginasthma.org]
   Google Scholar
• Juniper EF, Jenkins C, Price MJ, James MH. Impact of inhaled salmeterol/fluticasone propionate combination product versus budesonide on the health-related quality of life of patients with asthma. Am J Respir Med 2002;1:435–40
   PubMedGoogle Scholar
• Draft Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Rockville, MD: Food and Drug Administration; 2006
   Google Scholar
• Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997;155:1283–9
   PubMed Web of Science ®Google Scholar
• van Schayck CP, Dompeling E, Rutten MP, et al. The influence of an inhaled steroid on quality of life in patients with asthma or COPD. Chest 1995;107:1199–205
   PubMed Web of Science ®Google Scholar
• Corren J, Korenblat P, Miller C, et al. Twelve-week, randomized, placebo-controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered-dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma. Clin Ther 2007;29:823–43
   PubMed Web of Science ®Google Scholar
• American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Resp Dis 1987;136:225–44
   PubMed Web of Science ®Google Scholar
• Juniper EF, Guyatt GH, Epstein RS, et al. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992;47:76–83
   PubMed Web of Science ®Google Scholar
• Juniper EF, Buist AS, Cox FM, et al. Validation of a standardized version of the Asthma Quality of Life Questionnaire. Chest 1999;115:1265–70
   PubMed Web of Science ®Google Scholar
• Bushnell DM, Martin ML, Parasuraman B. Electronic versus paper questionnaires: a further comparison in persons with asthma. J Asthma 2003;40:751–62
   Google Scholar
• Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol 1994;47:81–7
   PubMed Web of Science ®Google Scholar
• Hays RD, Stewart AL. Sleep measures: definitions and issues. Measuring functioning and well-being. The medical outcomes study approach. In: Stewart AL, Ware JE, eds. Durham, NC: Duke University Press, 1992:235–59
   Google Scholar
• Mathias SD, Warren EH, Colwell HH, Sung JC. A new treatment satisfaction measure for asthmatics: a validation study. Qual Life Res 2000;9:873–82
   PubMed Web of Science ®Google Scholar
• Westfall PH, Ho SY, Prillaman BA. Properties of multiple intersection-union tests for multiple endpoints in combination therapy trials. J Biopharm Stat 2001;11:125–38
   Google Scholar
• Frison L, Pocock SJ. Repeated measures in clinical trials: analysis using mean summary statistics and its implications for design. Stat Med 1992;11:1685–1704
   PubMed Web of Science ®Google Scholar
• Juniper EF, Svensson K, O’Byrne PM, et al. Asthma quality of life during 1 year of treatment with budesonide with or without formoterol. Eur Respir J 1999;14: 1038–43
   Google Scholar
• Bergmann KC, Lindemann L, Braun R, Steinkamp G. Sal-meterol/fluticasone propionate (50/250 microg) combination is superior to double dose fluticasone (500 microg) for the treatment of symptomatic moderate asthma. Swiss Med Wkly 2004;134:50–8
   PubMed Web of Science ®Google Scholar
• Center for Drug Evaluation and Research. ADVAIR DISKUS (Fluticasone Propionate and Salmeterol Xinafoate) Inhalation Powder. Application number: 21–077. Available at: http://www.fda.gov/cder/foi/nda/2000/21077_AdvairDiskus.htm. [Last accessed March 2007]
   Google Scholar
• Chuchalin AG, Svensson K, Stahl E, et al. A health-related quality-of-life comparison of formoterol (Oxis) Turbuhaler plus budesonide (Pulmicort) Turbuhaler with budesonide Turbuhaler alone and noncorticosteroid treatment in asthma: a randomized clinical study in Russia. Respiration 2002;69:427–33
   PubMed Web of Science ®Google Scholar
• Noonan M, Rosenwasser LJ, Martin P, et al. Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma. Drugs 2006;66:2235–54
   PubMed Web of Science ®Google Scholar
• Miller CJ, Senn S, Mezzanotte WS. Bronchodilation of formoterol administered with budesonide: device and formulation effects. Contemp Clin Trials 2007 Jun 7 [epub ahead of print: doi:10.1016/j.cct.2007.05.008]
   Google Scholar